Merus N.V. has reported its financial results for the second quarter of 2025. The company experienced an increase in total revenue for the three months ending June 30, 2025, rising by $1.5 million compared to the same period in 2024. This growth was primarily driven by higher revenues from partnerships with Incyte, PTx, and Gilead, with respective increases of $1.5 million, $0.5 million, and $0.1 million. For the six months ending June 30, 2025, Merus reported collaboration revenue of $22 million, up from $15.2 million in the corresponding period of 2024. The company also reported commercial material revenue of $13.3 million for the same period in 2025, compared to none in 2024. As of June 30, 2025, Merus had cash, cash equivalents, and marketable securities totaling $892 million. The company expects these resources, along with the proceeds from a recent public offering, to finance operations until at least 2028. In terms of business development, Merus highlighted the promising results of its Phase II study on Petosemtamab, combined with Pembrolizumab, which showed a 63% response rate in treating PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma. The study also reported a 79% overall survival rate at 12 months.